120 related articles for article (PubMed ID: 1451073)
1. A randomized trial of accelerated hyperfractionated radiation therapy and bis-chloroethyl nitrosourea for malignant glioma. A preliminary report of Radiation Therapy Oncology Group 83-02.
Curran WJ; Scott CB; Nelson JS; Weinstein AS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG; Powlis WD
Cancer; 1992 Dec; 70(12):2909-17. PubMed ID: 1451073
[TBL] [Abstract][Full Text] [Related]
2. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02.
Werner-Wasik M; Scott CB; Nelson DF; Gaspar LE; Murray KJ; Fischbach JA; Nelson JS; Weinstein AS; Curran WJ
Cancer; 1996 Apr; 77(8):1535-43. PubMed ID: 8608540
[TBL] [Abstract][Full Text] [Related]
3. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
[TBL] [Abstract][Full Text] [Related]
4. NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients.
Ali AN; Zhang P; Yung WKA; Chen Y; Movsas B; Urtasun RC; Jones CU; Choi KN; Michalski JM; Fischbach AJ; Markoe AM; Schultz CJ; Penas-Prado M; Garg MK; Hartford AC; Kim HE; Won M; Curran WJ
J Neurooncol; 2018 Mar; 137(1):39-47. PubMed ID: 29404979
[TBL] [Abstract][Full Text] [Related]
5. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Nelson DF; Curran WJ; Scott C; Nelson JS; Weinstein AS; Ahmad K; Constine LS; Murray K; Powlis WD; Mohiuddin M
Int J Radiat Oncol Biol Phys; 1993 Jan; 25(2):193-207. PubMed ID: 8380567
[TBL] [Abstract][Full Text] [Related]
6. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
[TBL] [Abstract][Full Text] [Related]
7. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02).
Corn BW; Yousem DM; Scott CB; Rotman M; Asbell SO; Nelson DF; Martin L; Curran WJ
Cancer; 1994 Nov; 74(10):2828-35. PubMed ID: 7954244
[TBL] [Abstract][Full Text] [Related]
8. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02.
Curran WJ; Scott CB; Weinstein AS; Martin LA; Nelson JS; Phillips TL; Murray K; Fischbach AJ; Yakar D; Schwade JG
J Clin Oncol; 1993 May; 11(5):857-62. PubMed ID: 8487050
[TBL] [Abstract][Full Text] [Related]
9. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study.
Nelson DF; Diener-West M; Weinstein AS; Schoenfeld D; Nelson JS; Sause WT; Chang CH; Goodman R; Carabell S
Int J Radiat Oncol Biol Phys; 1986 Oct; 12(10):1793-800. PubMed ID: 3531110
[TBL] [Abstract][Full Text] [Related]
11. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Halperin EC; Gaspar L; Imperato J; Salter M; Herndon J; Dowling S
Am J Clin Oncol; 1993 Aug; 16(4):277-83. PubMed ID: 8392285
[TBL] [Abstract][Full Text] [Related]
12. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
[TBL] [Abstract][Full Text] [Related]
13. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group.
Nelson DF; Diener-West M; Horton J; Chang CH; Schoenfeld D; Nelson JS
NCI Monogr; 1988; (6):279-84. PubMed ID: 3281031
[TBL] [Abstract][Full Text] [Related]
14. Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Jeremic B; Grujicic D; Antunovic V; Djuric L; Shibamoto Y
Am J Clin Oncol; 1995 Oct; 18(5):449-53. PubMed ID: 7572767
[TBL] [Abstract][Full Text] [Related]
15. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
Westphal M; Hilt DC; Bortey E; Delavault P; Olivares R; Warnke PC; Whittle IR; Jääskeläinen J; Ram Z
Neuro Oncol; 2003 Apr; 5(2):79-88. PubMed ID: 12672279
[TBL] [Abstract][Full Text] [Related]
17. Imaging response in malignant glioma, RTOG 90-06.
Lustig RA; Seiferheld W; Berkey B; Yung AW; Scarantino C; Movsas B; Jones CU; Simpson JR; Fishbach J; Curran WJ
Am J Clin Oncol; 2007 Feb; 30(1):32-7. PubMed ID: 17278892
[TBL] [Abstract][Full Text] [Related]
18. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
19. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
Dinapoli RP; Brown LD; Arusell RM; Earle JD; O'Fallon JR; Buckner JC; Scheithauer BW; Krook JE; Tschetter LK; Maier JA
J Clin Oncol; 1993 Jul; 11(7):1316-21. PubMed ID: 8315428
[TBL] [Abstract][Full Text] [Related]
20. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Deutsch M; Green SB; Strike TA; Burger PC; Robertson JT; Selker RG; Shapiro WR; Mealey J; Ransohoff J; Paoletti P
Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1389-96. PubMed ID: 2542193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
